• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Circio Holding

Less than 1K followers

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
31.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Regulatory press release24.06.2026 klo 08.00

Circio and Tcelltech jointly announce CAR-T cell therapy research collaboration

Circio Holding
Regulatory press release22.06.2026 klo 15.05

Circio Holding ASA – Share capital increase registered

Circio Holding
Regulatory press release18.06.2026 klo 12.02

CIRCIO HOLDING ASA – SHARE CAPITAL INCREASE REGISTERED FOLLOWING EXERCISE OF WARRANTS AND UNDERWRITTEN PRIVATE PLACEMENT

Circio Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release10.06.2026 klo 00.12

Circio completes transformational fundraising of NOK 300 million to strengthen its position as the global leader in circular RNA-based gene expression systems

Circio Holding
Regulatory press release09.06.2026 klo 08.00

Circio Holding ASA: Last day of the exercise period for the Warrants

Circio Holding
Regulatory press release04.06.2026 klo 10.41

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Regulatory press release03.06.2026 klo 08.00

Circio Holding ASA: Last day of trading in warrants

Circio Holding
Regulatory press release02.06.2026 klo 11.33

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Regulatory press release01.06.2026 klo 08.00

CRNA: Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Circio Holding
Press release01.06.2026 klo 08.00

Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Circio Holding
Regulatory press release29.05.2026 klo 08.00

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Regulatory press release28.05.2026 klo 08.00

Circio hosts live webcast today 28 May 2026 at 10:00 am CEST

Circio Holding
Press release28.05.2026 klo 08.00

Circio hosts live webcast today 28 May 2026 at 10:00 am CEST

Circio Holding
Regulatory press release27.05.2026 klo 08.00

CRNA: Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases

Circio Holding
Press release27.05.2026 klo 08.00

Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases

Circio Holding
Regulatory press release26.05.2026 klo 08.10

Announcement of the terms of the underwriting and the Unused Warrants Option Agreement in connection with the Warrant Program

Circio Holding
Regulatory press release26.05.2026 klo 08.05

Commencement of exercise period for the Warrants

Circio Holding
Regulatory press release26.05.2026 klo 08.00

Warrants exercise period commences today – potential proceeds to transform Circio into a clinical-stage circular RNA company

Circio Holding
Regulatory press release22.05.2026 klo 19.11

Circio Holding ASA: Exercise price for Warrants set at NOK 8.2508

Circio Holding
Regulatory press release22.05.2026 klo 08.00

CRNA: Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program

Circio Holding